Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | HTR3A | P46098 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992970 | 0.87 | KMT2A (0.56) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL1996892 | 0.85 | HTR3A (0.62) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL5910624 | 0.82 | KMT2A (0.69) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL28538954 | 0.81 | KDM4E (0.98) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL28455263 | 0.77 | KDM4E (0.75) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL14691897 | 0.75 | GRIN2D (0.50) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL2998031 | 0.74 | KDM4E (0.61) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL30964777 | 0.74 | KDM4E (0.61) | KDM4EALDH1A1KMT2AMEN1USP2 | |
| SCHEMBL6663891 | 0.74 | NCF1 (0.51) | KMT2AMEN1USP2POLB | |
| SCHEMBL15919425 | 0.74 | ACACA (0.48) | KDM4EALDH1A1KMT2AMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | KDM4E 3351/4885ALDH1A1 297/4885KMT2A 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.